Chan Henry Lee sold $220k of ONC
SVP, General Counsel at BeiGene, Ltd.. 664 shares at an average of $331.76, traded Jan 7, 2026, filed Jan 9, 2026.
Score components
- +15RoleOfficer
- +12Trade size$220k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +4.7%, 3m -8.4%, 6m -11.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001980648-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 7, 2026 | MOption exercise American Depositary Shares10b5-1 | +202 | $194.47 | $39k | 202 | Jan 9, 2026 |
| Jan 7, 2026 | MOption exercise American Depositary Shares10b5-1 | +266 | $213.32 | $57k | 468 | Jan 9, 2026 |
| Jan 7, 2026 | MOption exercise American Depositary Shares10b5-1 | +196 | $159.03 | $31k | 664 | Jan 9, 2026 |
| Jan 7, 2026 | SOpen-market sale American Depositary Shares10b5-1 | -664 | $331.76 | $220k | 0 | Jan 9, 2026 |
| Jan 7, 2026 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -2,626 | $0.00 | $0 | 30,446 | Jan 9, 2026 |
| Jan 7, 2026 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -3,458 | $0.00 | $0 | 97,019 | Jan 9, 2026 |
| Jan 7, 2026 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -2,548 | $0.00 | $0 | 118,118 | Jan 9, 2026 |
Related signals
Other insiders at BeiGene, Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | BeiGene, Ltd. | Chan Henry Lee SVP, General Counsel | $418k 1,115 shares | -100% | |
| 33Weak | BeiGene, Ltd. | Xiaodong Wang director, other | $11M 31,028 shares | -100% | |
| 40Moderate | BeiGene, Ltd. | Xiaodong Wang director, other | $13M 38,287 shares | -527% | |
| 56Moderate | BeiGene, Ltd. | Titus B. Ball Principal Accounting Officer | $47k 132 shares | -100% | |
| 45Moderate | BeiGene, Ltd. | Xiaobin Wu President and COO | $106k 280 shares | -100% | |
| 39Weak | BeiGene, Ltd. | Chan Henry Lee SVP, General Counsel | $960k 2,666 shares | -100% | |
| 65Notable | BeiGene, Ltd. | John Oyler Chief Executive Officer | $86M 240,810 shares | -100% | |
| 72Notable | BeiGene, Ltd. | Aaron Rosenberg Chief Financial Officer | $362k 1,157 shares | -100% | |
| 65Notable | BeiGene, Ltd. | Chan Henry Lee SVP, General Counsel | $338k 1,044 shares | -100% | |
| 34Weak | BeiGene, Ltd. | Chan Henry Lee SVP, General Counsel | $542k 1,669 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.